Hanzandi Identifies Three Key Product Evolution Trends in the Booming Life Science Automation Industry

Many human choices are shaped by historical path dependence. For instance, when Zhao Jibin, a professional with a background in the life sciences industry, founded Hansundi, a life science automation company, his decision to establish liquid handling workstations as the company’s inaugural product line stemmed from his profound personal experience with pipetting during his student years.

As someone who has emerged from the laboratory setting, Zhao Jibin aims to develop and manufacture a core series of standalone instruments targeting “chokehold” technologies in the life sciences sector. This initiative seeks to liberate operators from extensive, repetitive, and mundane basic tasks while minimizing deviations and errors caused by manual handling.

Currently, Hanzandi has achieved breakthrough progress in the core standalone sector, forming a system centered onCANTUS SCREEN High-Throughput Liquid Handling Systema core portfolio of standalone products represented by .

In the course of continuously deepening its commitment to life science automation, HansaDi is also actively developing end-to-end automated systems for a diverse range of application scenarios, gradually establishing a comprehensive portfolio of fully automated solutions that span from simple benchtop workflow automation to the management of complex steps in large-scale system applications.

Currently, Hanzandi’s end-to-end automation, intelligence, and digitalization solutions have been widelyApplied to molecular diagnostics, clinical testing, small- and large-molecule drug screening, cell line development, and molecular screeningand other life science application areas.

Pipetting is the primary and fundamental step in all life science experiments. Pipetting accuracy has a significant impact on experimental results, and as detection scenarios expand, the requirements for pipetting precision continue to increase. A liquid handling workstation is an automated platform that replaces traditional pipetting tools, capable of automatically performing high-precision liquid handling tasks such as serial dilution, pipetting, and liquid pooling. It can also be integrated with detection instruments to achieve high-precision analysis of target analytes.

With the emergence of applications such as high-throughput PCR, DNA sequencing, drug development, and high-throughput screening, automated liquid handling platforms are becoming increasingly widespread. The absolute advantages of automated liquid handling workstations lie in reducing labor costs and improving the accuracy of sample preparation and liquid dispensing. Currently, the domestic market is still dominated by imported brands; however, some Chinese manufacturers have moved to the forefront of the industry, leveraging their comprehensive technical systems, robust product portfolios, and strong capabilities in product iteration and innovation.

CANTUS SCREEN High-Throughput Liquid Handling System by HanzandiIt is a feature-rich, high-speed, simple, efficient, and precise desktop multi-functional liquid handling system, consisting of five components: the pipetting module, monitoring module, workbench, safety door, and software.

CANTUS SCREEN High-Throughput Liquid Handling System Based onModular design, replaceable deck layout, customizable pipetting heads and grippers, and continuously upgraded software system, providing reliable operational support for users' diverse experimental needs.

While the highlight of technological innovation in automated liquid handling workstations lies in achieving cost-saving automation, safety, efficiency, and precision are the key performance indicators. Ensuring the tightness of each tip attachment, the consistency of liquid volume across each channel, and minimizing errors as much as possible are critical issues that liquid handling systems must address.

The pipetting module of the CANTUS SCREEN high-throughput liquid handling system adopts the air displacement principle. Rigorous testing has confirmed its reliable sealing and robustness, ensuring a perfect seal for each pipetting channel. It is compatible with pipette tips in various specifications, supporting liquid samples of different volumes, as well as pipetting operations involving variable heights and non-uniform spacing.Its optional pipetting range is 0.5 μL–1000 μL, with high pipetting accuracy, achieving ≤5% at 1 μL and ≤1% at 50 μL.

CANTUS SCREEN High-Throughput Liquid Handling System IncludesSingle-channel, 8-channel, 12-channel, multi-column, multi-row, and 96/384-channel pipetting modes, enabling more work to be completed in less time, significantly improvingSpeed and reproducibility of sample processing. This systemIt also features proprietary control software with an intuitive and user-friendly interface, enabling users to easily create, edit, and execute automated experimental protocols, thereby facilitating on-demand invocation and flexible combination of diverse applications.

The CANTUS SCREEN high-throughput liquid handling system is widely used in medical testing laboratories, gene sequencing companies, biopharmaceutical companies, and other fields due to its excellent flexibility and intelligence.

Currently, the Hanzandi standardized standalone platform coversCANTUS SCREEN High-Throughput Liquid Handling System, CANTUS FLEX Flexible Multi-Channel Liquid Handling Workstation, NEMO Full-Function Liquid Handling Workstation, VOLA Nucleic Acid Extractor, ARCO High-Precision Microliter Dispenseretc., serving nearly 100 research institutes and pharmaceutical companies with cost-effective products and services.

Moving beyond individual standalone products, Hanzandi aims to provide end-to-end automation, intelligence, and digitalization solutions for the life sciences industry from a holistic strategic perspective. To achieve this goal, Hanzandi has established a product strategy that spans research, development, and commercial operations, along with a comprehensive product portfolio covering both hardware and software platforms.

In terms of product strategy, Hanzandi divides the life science experimental process into seven major stages—foundational innovation, design and implementation, action decomposition, core standalone instruments, application methods, core applications, and research fields—following a path from underlying logic to high-level applications. Subsequently, each of these seven stages is further refined by breaking down all involved experimental steps into granular functional modules.

For instance, HanZanDi leveraged its proprietary resource advantages and comprehensive assessments of life sciences industry trends to determineAntibody Drugs, Synthetic Biology, In Vitro Diagnostics, Multi-omics, Cell Therapy, Organoids, and Brain ScienceSeven business research areas have refined core applications into more than 10 functional modules, including protein synthesis, cell line construction, high-throughput screening, and omics sample preparation.

Robust modular foundations and rapid module integration are key to Hanzandi’s automation development. Currently, Hanzandi offers more than 80 hardware modules, which are interconnected in process workflows by software systems empowered with digital technologies such as AI and IoT, ultimately building a bridge between bioprocessing and engineering languages.

Hanzandi integrates hardware modules, software-hardware systems, and laboratory consumables into a unified platform to rapidly respond to the personalized needs of diverse customers. This enables laboratories to operate more efficiently, conveniently, safely, and in compliance with regulations during testing, inspection, and R&D processes, thereby achieving cost reduction and efficiency improvement.

Currently, HanZanDi has designed and implemented six major solution platforms, includingHigh-Throughput Automated Synthetic Biology Screening and Detection Platform Solutions, High-Throughput Protein Drug Discovery and Screening Platform Solutions, High-Throughput Automated Small-Molecule Drug Screening Platform Solutions, High-Throughput Automated Microbial Screening Platform Solutions, Ultra-High-Throughput Viral Nucleic Acid Extraction and Detection Platform Solutions, Fully Automated Enzyme-Linked Immunosorbent Assay (ELISA) Platform Solutions.

It was revealed that Hanzandi will also leverage the unique applications of digital technologies such as AI and IoT in the life sciences sector to establish dedicated AI models and IoT systems from both biological and physical-logical perspectives, ultimately forming a comprehensive product portfolio that covers the entire chain of the smart laboratory and intelligent automated life sciences industry ecosystem.

China’s life sciences automation industry is still in its early stages of development, and the market landscape has yet to solidify. For companies to rapidly enhance their market influence, in addition to establishing high technical barriers and offering a diverse product portfolio, robust and agile delivery capabilities, along with effective project implementation and service management, are indispensable.

Take product delivery capability as an example. The delivery status of life science automation equipment directly impacts critical operations such as experimental execution and business continuity. For instance, suppliers capable of maintaining large-scale mass production and stable shipments despite international and domestic logistics constraints imposed by the pandemic are more likely to stand out.

Meanwhile, product delivery is not merely about the enterprise delivering the product on schedule; it also entails rapidly enabling the platform’s initial functionalities post-delivery.In 2021, Hanzandi won the bid for a high-throughput automated protein drug discovery and screening project at a renowned laboratory in China. Completing the work originally estimated to take at least 10 months in under six months, it set the fastest delivery record for systems of comparable scale within the industry, marking the quickest turnaround ever achieved by a Chinese brand for a large-scale integrated platform.

Furthermore, Hanzandi’s international team—combining expertise in life sciences product R&D, digital software architecture, automation engineering, and advanced industrial smart manufacturing—also serves as a testament to its own soft power.

In 2022, Hanzandi completed its nearly RMB 100 million Series A financing round, co-led by Prostar Capital and Hillhouse Ventures. The company will accelerate its in-depth layout in core standardized single-unit platforms, intelligent automated integration platforms, and personalized OEM/ODM platforms for instruments and systems, advancing together with the broader trend of domestication in the life sciences industry.